Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%

MT Newswires Live

6 hours ago

Neuren Pharmaceuticals (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.

Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.

Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.

Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614060270"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614060270\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614060270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614060270","market":"us","top_or_hot":-1,"title":"Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.</p><p>Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of <a href=\"https://laohu8.com/S/HIT\">Health in</a> Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.</p><p>Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.</p><p>Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-26 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.</p><p>Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of <a href=\"https://laohu8.com/S/HIT\">Health in</a> Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.</p><p>Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.</p><p>Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614060270","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614060270","pubTimestamp":1772078605,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals  said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7096":"制药"},"translate_title":"Neuren Pharmaceuticals表示，美国合作伙伴报告2025年第四季度Daybue销售额较高；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1},"content_text":"Neuren Pharmaceuticals (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}